1. Home
  2. ENTA vs OPRX Comparison

ENTA vs OPRX Comparison

Compare ENTA & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • OPRX
  • Stock Information
  • Founded
  • ENTA 1995
  • OPRX 2006
  • Country
  • ENTA United States
  • OPRX United States
  • Employees
  • ENTA N/A
  • OPRX N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • OPRX Business Services
  • Sector
  • ENTA Health Care
  • OPRX Consumer Discretionary
  • Exchange
  • ENTA Nasdaq
  • OPRX Nasdaq
  • Market Cap
  • ENTA 154.0M
  • OPRX 154.9M
  • IPO Year
  • ENTA 2013
  • OPRX N/A
  • Fundamental
  • Price
  • ENTA $5.27
  • OPRX $9.99
  • Analyst Decision
  • ENTA Buy
  • OPRX Buy
  • Analyst Count
  • ENTA 4
  • OPRX 8
  • Target Price
  • ENTA $17.25
  • OPRX $9.06
  • AVG Volume (30 Days)
  • ENTA 194.0K
  • OPRX 147.0K
  • Earning Date
  • ENTA 05-20-2025
  • OPRX 05-12-2025
  • Dividend Yield
  • ENTA N/A
  • OPRX N/A
  • EPS Growth
  • ENTA N/A
  • OPRX N/A
  • EPS
  • ENTA N/A
  • OPRX N/A
  • Revenue
  • ENTA $66,590,999.00
  • OPRX $92,127,000.00
  • Revenue This Year
  • ENTA N/A
  • OPRX $12.12
  • Revenue Next Year
  • ENTA N/A
  • OPRX $10.87
  • P/E Ratio
  • ENTA N/A
  • OPRX N/A
  • Revenue Growth
  • ENTA N/A
  • OPRX 28.81
  • 52 Week Low
  • ENTA $4.09
  • OPRX $3.78
  • 52 Week High
  • ENTA $17.24
  • OPRX $14.13
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 45.38
  • OPRX 66.74
  • Support Level
  • ENTA $4.96
  • OPRX $9.12
  • Resistance Level
  • ENTA $6.23
  • OPRX $10.40
  • Average True Range (ATR)
  • ENTA 0.33
  • OPRX 0.64
  • MACD
  • ENTA -0.01
  • OPRX 0.06
  • Stochastic Oscillator
  • ENTA 24.41
  • OPRX 82.25

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About OPRX OptimizeRx Corporation

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Share on Social Networks: